- about us
- medical affairs
- investors & media
- Email Alerts
- Contact Us
Except for the historical information contained herein, the matters set forth on this website, including statements regarding the Company’s drive to pursue the development and commercialization of three hormone replacement products, the Company’s focus and philosophy, and the focus of the Company’s subsidiaries, the Company’s belief that 42 million women in the US may benefit from hormone therapy, the Company’s growth strategy, the Company’s plans and regulatory strategy for the development of its proposed hormone therapy products, the Company’s belief in the advantages of its proposed hormone therapy products and the existing product offerings over competing products, and the Company’s plans to begin Phase 3 clinical trials, to evaluate various potential indications for its hormone technology, and to commercialize the proposed hormone therapy products, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including but not limited to: timely and successful completion of clinical studies and the results thereof; challenges and costs inherent in product marketing; the risks and uncertainties associated with economic and market conditions; risks and uncertainties associated with the Company’s business and finances in general; and other risks detailed in the Company’s filings with the U.S. Securities and Exchange Commission including its annual report on Form 10-K filed on March 12, 2013, reports on Form 10-Q and Form 8-K, and other such filings.
These forward-looking statements are based on current information that may change. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of this date. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or subsequent circumstances.